Insulin-like Growth Factor is Associated with Changes in Body Composition with ART Initiation.

Topic:

HIV Prevention

Authors:

Erlandson KM, Fiorillo SP, Wagner Cardosa S, Riviere C, Sanchez J, Hakim J, Kumarasamy N,Badal-Faesen S, Lalloo U, Kumwenda J, Campbell TB, Brown TT

External Link:

Link to article

BACKGROUND:

Growth hormone (GH)/insulin-like growth factor (IGF)-1 axis abnormalities have been associated with bodycomposition changes among HIV-infected persons with wasting or lipodystrophy. Little is known of GH/IGF-1 axis alterations with ARTinitiation or differing ART therapies.

METHODS:

The AIDS Clinical Trials Group Prospective Evaluation of Antiretrovirals in Resource- Limited Settings (PEARLS) study was a prospective, randomized clinical trial of ART initiation with emtricitabine/tenofovir + efavirenz (FTC/TDF+EFV) vs lamivudine/zidovudine + efavirenz (3TC/ZDV+EFV) in HIV-1-infected individuals from resource-diverse settings. IGF-1 was measured from baseline, week 48, and week 96 stored serum samples. Multivariate models were constructed.

RESULTS:

415 participants were included: 170 (41%) were randomized to FTC/TDF+EFV and 245 (59%) to 3TC/ZDV+EFV. The mean age was 35 years, 60% were black, 42% women. The mean IGF-1 level did not change significantly from baseline to week 96 (-0.65 ng/mL; CI -5.18, 3.87), p=0.78 and there were no differences by treatment arm at week 96, p=0.74. Lower baseline IGF-1 was associated with age, non-white race, greater waist-hip ratio (WHR), low CD4 count and lower baseline albumin (all p<0.01) but not plasma HIV-1 RNA, body mass index (BMI), or treatment arm. Greater change in IGF-1 from baseline to 96 weeks was associated with female sex, smaller WHR change, lower baseline albumin and higher baseline HIV-1 RNA (all p<0.01).

CONCLUSIONS:

ART initiation with either ZDV or TDF did not significantly impact overall IGF-1 levels. Baseline and on-treatment changes in IGF-1 with ART initiation may be related to the body composition changes that occur after ART initiation.

AIDS Res Hum Retro, 2017, in press 

Categories

CRS
Topics

Clinical Trials

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5308: A Prospective, Single-Arm, Open-Label Study to...

This study is being done with people who are infected with HIV, but do not show any signs of having HIV. They are also feeling...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More